Fresenius Kabi
Fabrizio Dolfi, MD, PhD, currently serves as the VP Head of Medical Affairs at Fresenius Kabi since February 2023. Previously, Fabrizio held the position of Senior Director Global Medical Affairs at Sobi - Swedish Orphan Biovitrum AB, focusing on rare diseases, CRS, and COVID-19. Fabrizio's expertise extends to consulting for pharmaceutical and biotech industries, contributing to clinical development strategies for atopic dermatitis at Arena Pharmaceuticals. Additional experience includes roles as Global Head of Medical Affairs and Promotional Compliance at Almirall, Franchise Medical Head for Immunology & Dermatology at Novartis, and Head of Clinical Development at Advanced Accelerator Applications. Preliminary roles involved leading medical affairs at NicOx and Galderma, as well as research positions at Sanford-Burnham Medical Research Institute and the University of California, San Diego. Education includes a Doctor of Philosophy in Molecular Biology and an MD in Medicine from Università degli Studi di Firenze.
This person is not in the org chart
This person is not in any offices
Fresenius Kabi
15 followers
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.